Asia
SinoMab Presents Preclinical Study Data of Vitiligo, Alopecia Drug at Dermatology Conference
SinoMab BioScience (HKG:3681) presented the results of preclinical studies of its hC2 at the Society for Investigative Dermatology Annual Meeting 2026 in Chicago on Thursday, according to a same-day Hong Kong bourse filing.In the preclinical study of the drug in humanized animal models for alopecia areata and vitiligo, hC2 showed favorable tolerability.
HKG:3681
